Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) EBT Margin (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed EBT Margin for 7 consecutive years, with 17690.09% as the latest value for Q2 2022.

  • On a quarterly basis, EBT Margin rose 1012263456.0% to 17690.09% in Q2 2022 year-over-year; TTM through Mar 2023 was 56526.81%, a 463321.0% increase, with the full-year FY2025 number at 1401.16%, changed N/A from a year prior.
  • EBT Margin was 17690.09% for Q2 2022 at Crescent Biopharma, up from 98847.07% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 85.14% in Q1 2020 to a low of 10140324.65% in Q2 2021.
  • A 3-year average of 1286155.83% and a median of 13620.79% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -8929557bps in 2021, then skyrocketed 1012263456bps in 2022.
  • Crescent Biopharma's EBT Margin stood at 9551.5% in 2020, then crashed by -935bps to 98847.07% in 2021, then soared by 82bps to 17690.09% in 2022.
  • Per Business Quant, the three most recent readings for CBIO's EBT Margin are 17690.09% (Q2 2022), 98847.07% (Q4 2021), and 20023.48% (Q3 2021).